Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Medical School Cancer Institute, Shanghai.
Translational Medical Center, Xiamen University, Xiamen.
Ann Oncol. 2013 Jul;24(7):1822-1827. doi: 10.1093/annonc/mdt071. Epub 2013 Mar 20.
To determine the prevalence and clinicopathological features of ROS1 fusions in Chinese patients with non-small-cell lung cancer (NSCLC).
Formalin-fixed and paraffin-embedded (FFPE) tissue sections from 392 patients with NSCLC were screened for ROS1 fusions by multiplex RT-PCR and all ROS1 fusions were validated by direct sequencing. The relationship between ROS1 fusions and clinicopathological features and the prognostic effect of the ROS1 fusion status on survival were analyzed.
In this study, 8 of 392 (2.0%) evaluable samples were found to harbor ROS1 fusions. Of the ROS1-positive patients, seven presented with adenocarcinoma, and one with adenosquamous carcinoma. The ratio of female to male and never smoker to smokers in a ROS1 fusion-positive group was 5:3. There was no statistically significant difference in age, sex, smoking history, histological type and pathological stage between ROS1 fusion-positive and ROS1 fusion-negative patients. ROS1 fusion-negative patients had a significantly longer survival when compared with ROS1 fusion-positive patients (P = 0.041). Lower pathological stage, younger age and ROS1 fusion-negative status were significantly associated with better prognosis on multivariate analysis.
ROS1 fusions occurred in ∼2.0% of Chinese patients with NSCLC and had no specific clinicopathological feature. ROS1 fusion-negative patients may have a better survival than ROS1 fusion-positive patients.
为了确定 ROS1 融合在中国非小细胞肺癌（NSCLC）患者中的流行率和临床病理特征。
通过多重 RT-PCR 对 392 例 NSCLC 患者的福尔马林固定石蜡包埋（FFPE）组织切片进行 ROS1 融合筛选，并通过直接测序验证所有 ROS1 融合。分析 ROS1 融合与临床病理特征的关系以及 ROS1 融合状态对生存的预后影响。
在这项研究中，在 392 个可评估样本中有 8 个被发现携带 ROS1 融合。在 ROS1 阳性患者中，7 例为腺癌，1 例为腺鳞癌。ROS1 融合阳性组中女性与男性的比例和从不吸烟者与吸烟者的比例为 5:3。ROS1 融合阳性与 ROS1 融合阴性患者在年龄、性别、吸烟史、组织学类型和病理分期方面无统计学差异。与 ROS1 融合阳性患者相比，ROS1 融合阴性患者的生存时间明显更长（P=0.041）。多因素分析显示，较低的病理分期、较年轻的年龄和 ROS1 融合阴性状态与更好的预后显著相关。
ROS1 融合在中国 NSCLC 患者中的发生率约为 2.0%，并无特定的临床病理特征。ROS1 融合阴性患者的生存可能优于 ROS1 融合阳性患者。
